ECSP19048477A - Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades - Google Patents
Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedadesInfo
- Publication number
- ECSP19048477A ECSP19048477A ECSENADI201948477A ECDI201948477A ECSP19048477A EC SP19048477 A ECSP19048477 A EC SP19048477A EC SENADI201948477 A ECSENADI201948477 A EC SENADI201948477A EC DI201948477 A ECDI201948477 A EC DI201948477A EC SP19048477 A ECSP19048477 A EC SP19048477A
- Authority
- EC
- Ecuador
- Prior art keywords
- disease
- dlk
- resulting
- diseases
- leucine zipper
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En este documento se dan a conocer compuestos que inhiben la actividad de cinasa de la cinasa de cremallera de leucina dual (DLK) (MAP3K12), composiciones farmacéuticas y métodos de tratamiento de enfermedades mediadas por DLK, tales como enfermedades neurológicas que resultan de lesión traumática al sistema nervioso central y neuronas del sistema nervioso periférico (por ejemplo, apoplejía, lesión cerebral traumática, lesión de médula espinal), o que resultan de un padecimiento neurodegenerativo crónico (por ejemplo, enfermedad de Alzheimer, demencia frontotemporal, enfermedad de Parkinson, enfermedad de Huntington, esclerosis lateral amiotrófica, ataxia espinocerebelar, parálisis supranuclear progresiva, enfermedad de cuerpos de Lewy, enfermedad de Kennedy y otros padecimientos relacionados), de neuropatías que resultan de daño neurológico (neuropatía periférica inducida por quimioterapia, neuropatía diabética y trastornos relacionados) y de trastornos cognitivos ocasionados por intervención farmacológica (por ejemplo, trastorno cognitivo inducido por quimioterapia, también conocido como quimiocerebro).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662431504P | 2016-12-08 | 2016-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19048477A true ECSP19048477A (es) | 2019-07-31 |
Family
ID=62492159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201948477A ECSP19048477A (es) | 2016-12-08 | 2019-07-08 | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades |
Country Status (17)
Country | Link |
---|---|
US (3) | US10093664B2 (es) |
EP (1) | EP3551610B1 (es) |
JP (1) | JP7128816B2 (es) |
KR (1) | KR20190087622A (es) |
CN (1) | CN110191878B (es) |
AU (1) | AU2017371084B2 (es) |
BR (1) | BR112019011801A2 (es) |
CA (1) | CA3045947A1 (es) |
CL (1) | CL2019001539A1 (es) |
CO (1) | CO2019006785A2 (es) |
EA (1) | EA201991375A1 (es) |
EC (1) | ECSP19048477A (es) |
ES (1) | ES2895257T3 (es) |
IL (1) | IL267121B (es) |
MX (1) | MX2019006645A (es) |
WO (1) | WO2018107072A1 (es) |
ZA (1) | ZA201904402B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190087622A (ko) | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제 |
IL301709A (en) | 2017-08-09 | 2023-05-01 | Denali Therapeutics Inc | Compounds, preparations and methods |
WO2019241244A1 (en) * | 2018-06-13 | 2019-12-19 | Board Of Regents, The University Of Texas System | Salts of bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
GB201811165D0 (en) * | 2018-07-06 | 2018-08-29 | Metrion Biosciences Ltd | Novel compounds |
US11702425B2 (en) * | 2018-08-01 | 2023-07-18 | Agency For Science, Technology And Research | Bicyclic compounds as kinase modulators, methods and uses thereof |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
CR20210426A (es) | 2019-02-13 | 2021-09-30 | Denali Therapeutics Inc | Compuestos, composiciones y métodos |
US11560366B2 (en) * | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
EP4208455A1 (en) * | 2020-09-02 | 2023-07-12 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Lzk-targeting degraders and methods of use |
AU2022340743A1 (en) * | 2021-09-01 | 2024-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mixed lineage kinase inhibitors and methods of use |
CN115974795A (zh) * | 2022-12-26 | 2023-04-18 | 杭州师范大学 | 一种含全氟烷基和n杂环二取代双环[1.1.1]戊烷及其合成方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2523134A1 (en) | 2003-04-25 | 2004-11-11 | Chiron Corporation | Pyridyl substituted ketolide antibiotics |
TW200944520A (en) | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
JP6267193B2 (ja) | 2012-05-22 | 2018-01-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 置換ジピリジルアミン類及びそれらの使用 |
CA2896187A1 (en) * | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | 3-substituted pyrazoles and use as dlk inhibitors |
CN104119340A (zh) | 2013-01-22 | 2014-10-29 | 韩冰 | 一类蛋白酶抑制剂及其制备方法和用途 |
CN105164114B (zh) | 2013-05-01 | 2018-03-23 | 豪夫迈·罗氏有限公司 | C‑连接的杂环烷基取代的嘧啶类和它们的用途 |
MY182082A (en) | 2013-05-01 | 2021-01-18 | Hoffmann La Roche | Biheteroaryl compounds and uses thereof |
MX2016008110A (es) | 2013-12-20 | 2016-08-19 | Hoffmann La Roche | Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos. |
CA2942144C (en) * | 2014-03-07 | 2023-08-22 | Kalyra Pharmaceuticals, Inc. | Propellane derivates and synthesis |
US9307840B2 (en) | 2014-07-01 | 2016-04-12 | Carlos Arturo Restrepo | Foldable and portable lounge chair having an integrated lockable storage compartment |
MY186133A (en) * | 2015-03-02 | 2021-06-24 | Rigel Pharmaceuticals Inc | Tgf-? inhibitors |
US10525036B2 (en) * | 2015-04-03 | 2020-01-07 | Recurium Ip Holdings, Llc | Spirocyclic compounds |
US20180057507A1 (en) * | 2016-08-29 | 2018-03-01 | Board Of Regents, The University Of Texas System | Inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
KR20190087622A (ko) | 2016-12-08 | 2019-07-24 | 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 | 질환 치료를 위한 이중 류신 지퍼 (dlk) 키나아제의 바이시클로[1.1.1]펜탄 억제제 |
US11560366B2 (en) * | 2019-10-21 | 2023-01-24 | Board Of Regents, The University Of Texas System | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease |
-
2017
- 2017-12-08 KR KR1020197019246A patent/KR20190087622A/ko active IP Right Grant
- 2017-12-08 MX MX2019006645A patent/MX2019006645A/es unknown
- 2017-12-08 EA EA201991375A patent/EA201991375A1/ru unknown
- 2017-12-08 JP JP2019530500A patent/JP7128816B2/ja active Active
- 2017-12-08 AU AU2017371084A patent/AU2017371084B2/en active Active
- 2017-12-08 WO PCT/US2017/065385 patent/WO2018107072A1/en unknown
- 2017-12-08 ES ES17879488T patent/ES2895257T3/es active Active
- 2017-12-08 CA CA3045947A patent/CA3045947A1/en active Pending
- 2017-12-08 US US15/836,442 patent/US10093664B2/en active Active
- 2017-12-08 CN CN201780082917.2A patent/CN110191878B/zh active Active
- 2017-12-08 BR BR112019011801-2A patent/BR112019011801A2/pt unknown
- 2017-12-08 EP EP17879488.9A patent/EP3551610B1/en active Active
-
2018
- 2018-09-04 US US16/121,198 patent/US10428057B2/en active Active
-
2019
- 2019-06-05 IL IL267121A patent/IL267121B/en unknown
- 2019-06-05 CL CL2019001539A patent/CL2019001539A1/es unknown
- 2019-06-26 CO CONC2019/0006785A patent/CO2019006785A2/es unknown
- 2019-07-04 ZA ZA2019/04402A patent/ZA201904402B/en unknown
- 2019-07-08 EC ECSENADI201948477A patent/ECSP19048477A/es unknown
-
2022
- 2022-03-10 US US17/654,301 patent/US20220267311A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20190087622A (ko) | 2019-07-24 |
US20180186781A1 (en) | 2018-07-05 |
US20190092764A1 (en) | 2019-03-28 |
WO2018107072A1 (en) | 2018-06-14 |
IL267121A (en) | 2019-08-29 |
IL267121B (en) | 2021-12-01 |
EP3551610A1 (en) | 2019-10-16 |
EA201991375A1 (ru) | 2020-01-20 |
JP2020502092A (ja) | 2020-01-23 |
CL2019001539A1 (es) | 2019-08-23 |
EP3551610B1 (en) | 2021-08-11 |
AU2017371084A1 (en) | 2019-06-20 |
BR112019011801A2 (pt) | 2019-10-29 |
EP3551610A4 (en) | 2020-04-22 |
CN110191878A (zh) | 2019-08-30 |
AU2017371084B2 (en) | 2022-04-28 |
ES2895257T3 (es) | 2022-02-18 |
JP7128816B2 (ja) | 2022-08-31 |
MX2019006645A (es) | 2019-08-26 |
CN110191878B (zh) | 2023-05-26 |
CO2019006785A2 (es) | 2019-07-10 |
ZA201904402B (en) | 2020-12-23 |
US10428057B2 (en) | 2019-10-01 |
CA3045947A1 (en) | 2018-06-14 |
US20220267311A1 (en) | 2022-08-25 |
US10093664B2 (en) | 2018-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19048477A (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
ECSP19021843A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
DOP2018000204A (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
BR112018068538A2 (pt) | composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno. | |
DOP2018000031A (es) | DERIVADOS DE 1,1,1-TRIFLUORO-3-HIDROXIPROPAN-2-IL CARBAMATO y DERIVADOS DE 1,1,1-TRIFLUORO-4-HIDROXIBUTAN-2-IL CARBAMATO COMO INHIBIDORES DE MAGL | |
DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
EA201691602A1 (ru) | Комбинация баклофена, акампросата и среднецепочечных триглицеридов для лечения неврологических расстройств | |
ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
PH12018502211A1 (en) | Prodrug of amino acid derivative | |
BR112017019685A2 (pt) | composto, composição farmacêutica, uso de um composto ou um sal ou um solvato farmaceuticamente aceitável do mesmo, e, método para tratamento de uma doença ou condição | |
NI202000074A (es) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina | |
CU24647B1 (es) | Moduladores del receptor nmda heteroaromático | |
CO2019001060A2 (es) | Composiciones de reelina para el tratamiento de trastornos neurológicos | |
IN2013DN11328A (es) | ||
MX2020003844A (es) | Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en particular caracterizadas por una disminución de la plasticidad sináptica. | |
RU2014153894A (ru) | Способ предупреждения неврологических заболеваний | |
SG11201809845TA (en) | Benzodiazepine product with activity on the central nervous and vascular systems | |
WO2017103892A3 (en) | Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease | |
WO2014111525A3 (en) | Combination therapies for treating nervous system diseases | |
WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease | |
MX2019013717A (es) | Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia. | |
MX2017012239A (es) | Metodos y composiciones para la administracion intravenosa de fumaratos para el tratamiento de enfermedades neurologicas. | |
MX2016003878A (es) | Composicion, proceso de produccion y uso de composicion para tratamiento de desordenes del sistema nervioso central. | |
CL2012000539A1 (es) | Compuestos derivados de acido 3-(morfolin-4-il)-propionico, moduladores de s1p; composicion farmaceutica; utiles en el tratamiento, alivio o prvencion de enfermedades del sistema nervioso central, tales como trastornos neurodegenerativas, enfermedades de alzheimer, depresion mayor, autismo, entre otras. |